Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782003 | 1.00 | CYP1A2 (0.55) | CYP1A2CYP2C9HIF1APDE10AALPI | |
| Hydrochloric Acid SCHEMBL6408746 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2C9HIF1APDE10AALPI | |
| SCHEMBL19462808 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2C9HIF1APDE10AALPI | |
| SCHEMBL29430134 | 0.79 | CYP1A2 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL502039 | 0.79 | CYP1A2 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL839033 | 0.79 | CYP1A2 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL502040 | 0.79 | CYP1A2 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28044913 | 0.79 | SLC7A5 (0.59) | CYP1A2CYP2C9HIF1AALPIPKM | |
| SCHEMBL4529374 | 0.76 | CYP1A2 (0.50) | CYP1A2CYP2C9HIF1APDE10AHSD17B10 | |
| SCHEMBL31614353 | 0.76 | TPH1 (0.62) | HIF1AALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094171-A1 | SUPERHYDROPHOBIC COATING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-05-08 | — | — | WO | claimed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| EP-4401555-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-07-24 | — | — | EP | claimed |
| US-20230174596-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2023-06-08 | — | — | US | claimed |
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| CN-114805528-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114591422-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20200325187-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH, INC. (US) | 2020-10-15 | — | — | US | claimed |
| US-20200231636-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2020-07-23 | — | — | US | claimed |
| EP-2951195-B1 | ANTIFOULING MATERIALS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2020-02-19 | — | — | EP | claimed |
| EP-3374520-A1 | BIOSENSORS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-09-19 | — | — | EP | claimed |
| EP-3350215-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | H. Hoffnabb-La Roche Ag (CH) | 2018-07-25 | — | — | EP | claimed |
| CN-108026162-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2018-05-11 | — | — | CN | claimed |
| WO-2017081684-A1 | BIOSENSORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-18 | — | — | WO | claimed |
| US-20170129927-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2017-05-11 | — | — | US | claimed |
| US-9631100-B2 | Antifouling materials | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-04-25 | — | — | US | claimed |
| WO-2017049009-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH, INC. (US) | 2017-03-23 | — | — | WO | claimed |
| US-20150368480-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-12-24 | — | — | US | claimed |
| EP-2951195-A1 | ANTIFOULING MATERIALS | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2015-12-09 | — | — | EP | claimed |
| WO-2014118779-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | CYP1A2 4502/4885CYP2C9 3847/4885HIF1A 690/4885 |
| US-20150368480-A1 | ANTIFOULING MATERIALS | PFAS, FLNB, FLNA | CYP1A2 1080/4885CYP2C9 1078/4885HIF1A 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.